FDA approves Amneal’s self-administered migraine drug Brekiya

Brekiya is now the first DHE auto-injector to be approved by the regulator

FDA approves Click’s digital therapeutic for episodic migraine

More than 37 million adults in the US are affected by migraine

FDA approves Deciphera’s Romvimza for rare tumour type

Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations